AAP
VTGN icon

Ardsley Advisory Partners’s VistaGen Therapeutics VTGN Stock Holding History

Ardsley Advisory Partners’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-833
Closed -$32K – 181
2019
Q1 		$32K Buy
+833
New +$36.3K 0.01% 130

Other funds holding VTGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return

Ardsley Advisory Partners's VTGN Position: Q2 2019 in Review

Ardsley Advisory Partners sold out of VistaGen Therapeutics (VTGN) in Q2 2019, closing a stake of 833 shares — an estimated $32K sold.

Ardsley Advisory Partners first reported a position in VTGN in Q1 2019 and held it in 1 quarter. The position peaked at $32K in Q1 2019. 21 funds tracked by Wall St. Rank hold VTGN as of Q2 2019.

  • Ardsley Advisory Partners reported no remaining VistaGen Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Ardsley Advisory Partners sold 833 VistaGen Therapeutics shares in Q2 2019, an estimated $32K.
  • Ardsley Advisory Partners first reported a position in VistaGen Therapeutics in Q1 2019 and held it in 1 quarter.
  • Ardsley Advisory Partners's VistaGen Therapeutics position peaked at $32K in Q1 2019.
  • 21 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2019.

Based on Ardsley Advisory Partners's 13F filing for Q2 2019, filed 13 Aug 2019.